Business Context and Reporting Period
This Form 8-K was filed by GRI Bio, Inc. on March 10, 2025. The report addresses the Company's compliance status with The Nasdaq Stock Market LLC listing requirements, specifically regarding the Minimum Bid Price Rule.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event notification rather than a financial statement.
Material Changes
- Compliance Restoration: The Company received notification from Nasdaq that the bid price deficiency under Listing Rule 5550(a)(2), previously reported in September 2024, has been cured.
- Listing Status: GRI Bio, Inc. is now in compliance with the Minimum Bid Price Rule, resolving the prior delisting risk.
Outlook, Risks, and Management Commentary
On March 11, 2025, the Company issued a press release (Exhibit 99.1) confirming compliance with the Minimum Bid Price Rule. The filing indicates no new material risks or contingencies beyond the resolution of the previously disclosed listing deficiency.
Investor Verification Checklist
- Verify the current trading price of GRI Bio, Inc. (Symbol: GRI) on the Nasdaq Capital Market to confirm sustained compliance with the $1.00 minimum bid price requirement.
- Review the attached press release (Exhibit 99.1) for any additional operational updates or forward-looking statements.
- Monitor future filings to ensure the Company maintains compliance with other Nasdaq listing standards.